Alzamend Neuro, Inc.

WHO'M
ai
Digital Profiler. Simply click the AI button
CUSIP
02262M506
SEDOL
N/A
CIK
0001677077
www.alzamend.com
LEI:
©
FIGI: BBG00ZMXG7M8
ALZN
Alzamend Neuro, Inc.
GICS: - · Sector: Healthcare · Sub-Sector: Biotechnology
AI
PROFILER
NAME
Alzamend Neuro, Inc.
ISIN
US02262M5067
TICKER
ALZN
MIC
XNAS
REUTERS
ALZN.OQ
BLOOMBERG
ALZN US
BUILD THEMEFOLIO SHARE IDEAS DISCUSS
LEVERAGE INVEST
EN 728x90
Financial Intelligence
360° iHub Crowd iFeed ATH Tracker Index Tracker ETF TF Spicy2 X-Billboard
FOR INVESTORS
FOR TRADERS
Securities Trading Warrants
The X-News Explorer is the ultimate source of information for investors with an affinity for the stock market who want to get a quick and convenient overview of the current news situation of a listed company. Various newswire services are available to you here. If a news alert is displayed, you will find company news that may be of interest to you. This service is provided by BusinessWire.
Wed, 18.12.2024       Alzamend Neuro
US02262M5067

Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), a clinical-stage biopharmaceutical company, focused on developing novel products for the treatment of Alzheimer’s disease (“Alzheimer’s”), bipolar disorder (“BD”), major depressive disorder (“MDD”) and post-traumatic stress disorder (“PTSD”), today announced it will have a poster presentation at th...
Read More
Alzamend Neuro
Technical Analysis Termsheet Terminal
Permalink
Thu, 12.12.2024       Alzamend Neuro
US02262M5067

Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), a clinical-stage biopharmaceutical company, focused on developing novel products for the treatment of Alzheimer’s disease (“Alzheimer’s”), bipolar disorder (“BD”), major depressive disorder (“MDD”) and post-traumatic stress disorder (“PTSD”), reported its financial results for the second quarter en...
Read More
Alzamend Neuro
Technical Analysis Termsheet Terminal
Permalink
Tue, 19.11.2024       Alzamend Neuro
US02262M5067

Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease (“Alzheimer’s”), bipolar disorder (“BD”), major depressive disorder (“MDD”) and post-traumatic stress disorder (“PTSD”), today announced that it has finished analyzing the final ...
Read More
Alzamend Neuro
Technical Analysis Termsheet Terminal
Permalink
Wed, 16.10.2024       Alzamend Neuro
US02262M5067

Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease (“Alzheimer’s”), bipolar disorder (“BD”), major depressive disorder (“MDD”) and post-traumatic stress disorder (“PTSD”), today announced that it has received the final full data ...
Read More
Alzamend Neuro
Technical Analysis Termsheet Terminal
Permalink
Tue, 15.10.2024       Alzamend Neuro
US02262M5067

Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease (“Alzheimer’s”), bipolar disorder (“BD”), major depressive disorder (“MDD”) and post-traumatic stress disorder (“PTSD”), today announced that it has received formal written notic...
Read More
Alzamend Neuro
Technical Analysis Termsheet Terminal
Permalink
Thu, 10.10.2024       Alzamend Neuro
US02262M5067

Alzamend Neuro, Inc. (Nasdaq: ALZN) (“Alzamend”), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer’s disease (“Alzheimer’s”), bipolar disorder (“BD”), major depressive disorder (“MDD”) and post-traumatic stress disorder (“PTSD”), today announced that CEO Stephan Jackman will participate...
Read More
Alzamend Neuro
Technical Analysis Termsheet Terminal
Permalink
We are different
OPEN FINANCIAL
DATA & KNOWLEDGE HUB
We make the difference
Information on product placements

 

SMART * AD
EN GIF 970X250

P R O D U C T   S U G G E S T I O N S